Fletcher A, Alkjaersig N, Schonfeld G, Witztum J
Arteriosclerosis. 1981 May-Jun;1(3):202-9. doi: 10.1161/01.atv.1.3.202.
Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemia Types IIa, IIb, and IV, and in 24 control subjects with normal blood lipid values. Subjects with either a history of thromboembolic vascular disease or clinical evidence of atherosclerosis were excluded. Type II subjects (i.e., the combined group of Type IIa and IIb subjects) showed an elevation of plasma high molecular weight fibrinogen complexes, which is indicative of enhanced fibrin formation. They also showed an elevation of fibrinogen-first-derivative, which is indicative of fibrinogenolysis and increased plasma euglobulin activity. Subjects with Type IV hyperlipoproteinemia showed similar findings to those of Type II except that high molecular weight fibrinogen complex concentration was normal. Subsequently, 36 patients received a fat-controlled, low cholesterol diet and were studied in a blind, random, crossover study of dietary vs clofibrate treatment. Although total cholesterol and triglyceride levels fell significantly during the treatment periods, chromatographic findings of abnormal plasma fibrinogen remained unchanged.
通过血浆纤维蛋白原色谱法和其他方法，对99例IIa型、IIb型和IV型高脂蛋白血症患者以及24例血脂值正常的对照者进行了纤维蛋白原分解代谢研究。排除有血栓栓塞性血管疾病病史或动脉粥样硬化临床证据的受试者。II型受试者（即IIa型和IIb型受试者的合并组）血浆高分子量纤维蛋白原复合物升高，这表明纤维蛋白形成增强。他们还表现出纤维蛋白原一级衍生物升高，这表明纤维蛋白原溶解和血浆优球蛋白活性增加。IV型高脂蛋白血症患者的结果与II型患者相似，只是高分子量纤维蛋白原复合物浓度正常。随后，36例患者接受了脂肪控制、低胆固醇饮食，并在饮食与氯贝丁酯治疗的盲法、随机、交叉研究中进行了研究。尽管在治疗期间总胆固醇和甘油三酯水平显著下降，但血浆纤维蛋白原异常的色谱结果仍未改变。
